2023 ESMO前瞻｜乳腺癌領域重磅研究一覽！

2023年歐洲腫瘤內科學會（ESMO）年會將于10月20日-24日在西班牙馬德里召開。ESMO大會涵蓋基礎研究、轉化研究以及最新臨床研究進展，將為臨床實踐、多學科討論等提供廣闊、卓越的學術平臺。醫脈通特整理了乳腺癌領域重磅研究，以饗讀者。

日期：2023年10月20日，星期五

時間：14:00 – 15:40

主席：Stephen R. Johnston (London, United Kingdom)，Sara M. Tolaney (Boston, United States of America)

地點：Bilbao Auditorium – NCC

標題：Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes

報告人：Nadia Harbeck (Munich, Germany)

時間：14:00 – 14:10

標題：Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase 3 KEYNOTE-522 study

報告人：Peter Schmid (London, United Kingdom)

時間：14:10 – 14:20

標題：Event-free survival (EFS) analysis of neoadjuvant taxane/carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer (TNBC): NeoTRIP Michelangelo randomized study

報告人：Luca Gianni (Milan, Italy)

時間：14:20 – 14:30

標題：A randomized, double-blind trial of nivolumab (NIVO) vs placebo (PBO) with neoadjuvant chemotherapy (NACT) followed by adjuvant endocrine therapy (ET) ± NIVO in patients (pts) with high-risk, ER+ HER2? primary breast cancer (BC)

報告人：Sherene Loi (Melbourne, Australia)

時間：14:55 – 15:05

標題：KEYNOTE-756: Phase 3 study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer

報告人：Fatima Cardoso (Lisbon, Portugal)

時間：15:05 – 15:15

日期：2023年10月23日，星期一

時間：16:30 – 18:00

主席：Ines V. Vaz Luis (Villejuif, Cedex, France) ，Carsten Denkert (Marburg, Germany)， Ava Kwong (Hong Kong, Hong Kong PRC)

地點：Bilbao Auditorium – NCC

標題：Longterm residential and workplace exposure to air pollution and breast cancer risk: a case-control study nested in the French E3N cohort from 1990 to 2011

報告人：Beatrice Fervers (Lyon, France)

時間：16:30 – 16:35

標題：Connected device and therapeutic patient education to promote physical activity among in women with localized breast cancer: results from the DISCO randomized trial

報告人：Beatrice Fervers (Lyon, France)

時間：16:35 – 16:40

標題：Impact of body mass index and its change on survival outcomes in patients with early breast cancer: a pooled analysis of individual-level data from BCIRG-001 and BCIRG-005 trials

報告人：陳海珠（中國，廣州）

時間：16:40 – 16:45

標題：Prognostic and predictive impact of estrogen/progesterone receptor (ER/PR), and Ki-67 expression: an exploratory analysis from the monarchE trial in patients with high-risk, HR+, HER2-, early breast cancer (EBC)

報告人：Matthew P. Goetz (Rochester, United States of America)

時間：17:00 – 17:05

標題：Invasive disease–free survival (iDFS) across key subgroups from the Phase III NATALEE study of ribociclib (RIB) + a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2? early breast cancer (EBC)

報告人：Aditya Bardia (Boston, United States of America)

時間：17:05 – 17:10

標題：Patient characteristics and real-world outcomes in HER2 negative/ ER zero and ER low patients treated as triple-negative breast cancer in Sweden 2008-2020

報告人：Irma Fredriksson (Stockholm, Sweden)

時間：17:10 – 17:15

標題：Association of tumor-infiltrating lymphocytes (TILs) with Recurrence Score (RS) in patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) early breast cancer (BC) – a translational analysis of four prospective multicentric studies.

報告人：Federica Miglietta (Padova, Italy)

時間：17:15 – 17:20

標題：Multiparametric prognostic score in early HR+/HER2- breast cancer: impact of Recurrence Score, clinical-pathological factors, gene mutations and histology

報告人：Oleg Gluz (M?nchengladbach, Germany)

時間：17:20 – 17:25

標題：Omission of breast surgery after neoadjuvant systemic therapy for invasive cancer: three-year preplanned primary-endpoint on a phase 2 multicentre prospective trial

報告人：Henry M. Kuerer (Houston, United States of America)

時間：17:40 – 17:45

標題：A Phase II Trial Targeting Disseminated Dormant Tumor Cells with Hydroxychloroquine, Everolimus or the Combination to Prevent Recurrent Breast Cancer (“CLEVER”)

報告人：Angela DeMichele (Philadelphia, United States of America)

時間：17:45 – 17:50

日期：2023年10月21日，星期六

時間：10:15 – 11:35

主席：Hervé Bonnefoi (Bordeaux, France)， Janice Wing-Hang Tsang (Hong Kong, Hong Kong PRC)

地點：Barcelona Auditorium – Hall 9

標題：First-in-human/phase I trial of HS-20089, a B7-H4 ADC, in patients with advanced solid tumors

報告人：張劍（中國，上海）

時間：10:15 – 10:25

標題：Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase 3 DESTINY-Breast04 study

報告人：Shanu Modi (New York, United States of America)

時間：10:25 – 10:35

標題：A Pooled Analysis of Trastuzumab Deruxtecan (T-DXd) in Patients (pts) With HER2-Positive (HER2+) Metastatic Breast Cancer (mBC) With Brain Metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03

報告人：Sara A. Hurvitz (Santa Monica, United States of America)

時間：10:55 – 11:05

標題：Persistence under abemaciclib and endocrine treatment (ABA+ET) in patients with advanced breast cancer (aBC) – first results of the randomized IMPACT Trial comparing patient coaching with the MASCC Oral Agent Teaching Tool (MOATT) versus local routine patient coaching (LC).

報告人：Manfred K. Welslau (Aschaffenburg, Germany)

時間：11:05 – 11:15

日期：2023年10月22日，星期日

時間：08:30 – 09:55

主席：Barbara Pistilli (Villejuif, Cedex, France)， Christoph Thomssen (Halle, Germany)， Hervé Bonnefoi (Bordeaux, France)

地點：Bilbao Auditorium – NCC

標題：Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): updated results from BEGONIA, a phase 1b/2 study

報告人：Peter Schmid (London, United Kingdom)

時間：08:30 – 08:35

標題：SKB264 (MK-2870) in previously treated hormone receptor-positive (HR+)/ HER2-negative metastatic breast cancer (mBC): results from a phase I/II, single-arm, basket trial

報告人：殷詠梅（中國，南京）

時間：08:35 – 08:40

標題：Updated results from the phase 1/2 study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD ) in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast cancer.

報告人：Nancy U. Lin (Boston, United States of America)

時間：08:55 – 09:00

標題：Imlunestrant with or without everolimus or alpelisib, in ER+, HER2- advanced breast cancer (aBC): Results from the phase 1a/b EMBER study

報告人：Komal Jhaveri (New York, United States of America)

時間：09:00 – 09:05

標題：Final overall survival analysis for fulvestrant vs anastrozole in endocrine therapy (ET)-na?ve, hormone receptor-positive (HR+) advanced breast cancer (FALCON)

報告人：John Robertson (Nottingham, United Kingdom)

時間：09:05 – 09:10

標題：A multicenter, open-label, dose escalation and expansion study of DP303c in patients with HER2-positive pre-treated advanced solid tumors

報告人：杜益群（中國，上海）

時間：09:25 – 09:30

標題：Trastuzumab duocarmazine versus physician’s choice therapy in pre-treated HER2-positive metastatic breast cancer: final results of the phase III TULIP trial

報告人：Philippe G. Aftimos (Anderlecht, Belgium)

時間：09:30 – 09:35

標題：First Results of the SOLTI-1903 HOPE’s Patient-Centric Molecular Screening Program in Advanced Breast Cancer

報告人：Tomás Pascual (Barcelona, Spain)

時間：09:35 – 09:40